Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of natamycin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis

A technology for fatty liver disease and natamycin, applied in drug combinations, pharmaceutical formulations, metabolic diseases, etc., to achieve enhanced glucose tolerance, excellent preventive and therapeutic effects, and excellent preventive and/or therapeutic effects

Active Publication Date: 2022-08-05
亿药科技(苏州)有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, natamycin has not been reported for the prevention and / or treatment of NAFLD, NASH, obesity and diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of natamycin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis
  • Application of natamycin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis
  • Application of natamycin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease or hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Natamycin activity tested on mouse MCD models (NASH and NAFLD models):

[0037] Experimental methods: (1) 8-week-old C57BL / 6N were kept under environmental control and allowed free access to standard feed and water. After one week of adaptation, the mice were divided into two groups. The mice in the model group and the mice in the administration group were fed a diet deficient in methionine choline (MCD, A02082002B).

[0038] After being fed with MCD feed for two weeks, the mice in the administration group were intraperitoneally injected with a vehicle containing natamycin (3% DMSO, 0.5% CMC-Na in normal saline) once a day for 14 consecutive days (the dosage of natamycin was 10 mg). / Kg), the mice in the model group were injected with the vehicle at the same frequency. Mice were sacrificed after 14 days, and mouse body weight and liver tissue were weighed.

[0039] Sections of individual livers were fixed with 4% paraformaldehyde, and liver histological characteristic...

Embodiment 2

[0045] Natamycin activity was tested on high-fat+high-fructose-high glucose (HFD+HF / G) mouse models (NASH and NAFLD models):

[0046] Experimental methods: 8-week-old C57BL / 6N mice were divided into two groups after one week of adaptation to the new environment, the model group mice and the administration group mice, and were fed high-fat diet (60kcal%fat) at the same time.

[0047] After 8 weeks of high-fat diet, fructose and glucose (sigma) were added to drinking water, and after 12 weeks of high-fat, high-fructose and glucose feeding, the mice in the administration group were injected intraperitoneally with body weight once a day for 28 consecutive days The vehicle containing natamycin (3% DMSO, 0.5% CMC-Na in normal saline) (the dosage of natamycin is 5 mg / Kg), the mice in the model group were injected with the vehicle at the same frequency. Mice were sacrificed after 28 days, and mouse body weight and liver tissue were weighed.

[0048] Sections of individual livers were...

Embodiment 3

[0055] Natamycin was tested for anti-obesity activity on high-fat diet (HFD) and regular diet (WT) mice:

[0056] Experimental method: 8-week-old C57BL / 6N were divided into five groups after one week of adaptation to the new environment, namely HFD+Natamycin5mg / Kg group, HFD+Natamycin10mg / Kg group, HFD model group, WT+Natamycin10mg / Kg group and WT group . Mice in HFD+Natamycin5mg / Kg group, HFD+Natamycin10mg / Kg group and HFD model group were fed with high-fat diet (60kcal%fat) for 8 weeks. The WT+Natamycin10mg / Kg group and the WT group were fed with normal mouse growth and reproduction diets for 8 weeks. During this period, the mice in the HFD+Natamycin 5mg / Kg group, HFD+Natamycin 10mg / Kg group and WT+Natamycin 10mg / Kg group were injected intraperitoneally with vehicle (3% DMSO, 0.5% natamycin) by body weight once a day. CMC-Na normal saline) (the dosage of natamycin in the HFD+Natamycin5mg / Kg group is 5mg / Kg, the dosage of natamycin in the HFD+Natamycin10mg / Kg group and the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of natamycin in preparation of a medicine for preventing and / or treating a non-alcoholic fatty liver disease or hepatitis. Compared with the prior art, the invention discloses a novel medical application of natamycin, and finds that natamycin has an excellent effect of preventing and / or treating non-alcoholic fatty liver diseases or hepatitis, especially obesity-related or diabetes-related non-alcoholic fatty liver diseases or hepatitis. Besides, researches show that the natamycin can effectively reduce body weight, improve body energy consumption, reduce blood sugar and enhance glucose tolerance and insulin sensitivity, and shows that the natamycin also has excellent prevention and treatment effects on obesity and diabetes mellitus.

Description

technical field [0001] The invention belongs to the technical field of new medical application of natamycin, and particularly relates to the application of natamycin in the preparation of medicines for preventing and / or treating non-alcoholic fatty liver disease or hepatitis. Background technique [0002] With the improvement of living standards, non-alcoholic fatty liver disease (NAFLD) affects the health of more and more people. Non-alcoholic fatty liver disease (NAFLD) refers to a condition in which there is too much fat in the liver in people who drink little or no alcohol. The most common form of NAFLD is a non-serious condition called hepatic steatosis (fatty liver), in which fat builds up in liver cells: Although this is not normal, it may not damage the liver itself. NAFLD occurs most often in individuals with a range of risk factors known as metabolic syndrome, which is characterized by elevated fasting blood sugar, or intolerance to postprandial blood sugar, being...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P1/16A61P3/04A61P3/10
CPCA61K31/7048A61P1/16A61P3/04A61P3/10Y02A50/30
Inventor 王靖翔刘祖瑞谢正伟
Owner 亿药科技(苏州)有限公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com